Literature DB >> 6412898

Non-reversible and wide ranging voice changes after treatment with danazol.

P G Wardle, M I Whitehead, R P Mills.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6412898      PMCID： PMC1549218          DOI： 10.1136/bmj.287.6397.946

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN： 0267-0623


× No keyword cloud information.
  5 in total

1.  Long-term therapy of hereditary angioedema with danazol.

Authors:  S W Hosea; M L Santaella; E J Brown; M Berger; K Katusha; M M Frank
Journal:  Ann Intern Med       Date:  1980-12       Impact factor: 25.391

2.  Controlled trial of the antigonadotropin danazol in painful nodular benign breast disease.

Authors:  R E Mansel; J R Wisbey; L E Hughes
Journal:  Lancet       Date:  1982-04-24       Impact factor: 79.321

3.  Interim report a study of danazol for the treatment of endometriosis.

Authors:  V C Buttram; J B Belue; R Reiter
Journal:  Fertil Steril       Date:  1982-04       Impact factor: 7.329

4.  Danazol in the treatment of endometriosis: analysis of 100 cases with a 4-year follow-up.

Authors:  R L Barbieri; S Evans; R W Kistner
Journal:  Fertil Steril       Date:  1982-06       Impact factor: 7.329

5.  Reduction of menstrual blood loss by danazol in unexplained menorrhagia: lack of effect of placebo.

Authors:  T H Chimbira; A B Anderson; C Naish; E Cope; A C Turnbull
Journal:  Br J Obstet Gynaecol       Date:  1980-12
  5 in total
  2 in total

Review 1.  Benefits and risks of pharmacological agents used for the treatment of menorrhagia.

Authors:  Samendra Nath Roy; Siladitya Bhattacharya
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

Review 2.  A risk-benefit appraisal of drugs used in the management of premenstrual syndrome.

Authors:  J F Mortola
Journal:  Drug Saf       Date:  1994-02       Impact factor: 5.606
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.